The Musculoskeletal Tumours WG aims to obtain thorough information on the genetic and epigenetic alterations that characterize primary bone and muscle sarcomas and deepen the knowledge about bone microenvironment and the immune infiltration in these tumours to highlight therapeutic strategies that go beyond the use of current drugs.

Particular attention will be paid to the analysis of those patients who escape the first-line therapies, develop pharmacoresistance and progress with the formation of metastases.

The WG allows for collaborative work between clinical and preclinical researchers who have expertise in rare cancers, often pediatric, with site of onset in bones and/or muscles. Interaction with the Italian Sarcoma Group allows the analysis of the material collected in the various biobanks of the IRCCS in the clinical Phase I-III trial context, achieving results at the national level quickly. Within the framework of the WG technical skills, preclinical models, and scientific experiences of the different centers will be shared to perform functional analysis and/ or validate data originated from genomics.

The final purpose of the WG is to design a platform and procedures for genetic/biological studies included in clinical trials at the national and international level, as well as develop personalized medicine for cancers that still escape even the most modern therapeutic approaches.